Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in the place in the event that Gilead do not agree an interim access arrangement with NHS England following licensing of Trodelvy for metastatic triple negative breast cancer patients through Project Orbis.

NHS England and NHS Improvement and the National Institute for Health and Care Excellence (NICE) have agreed a set of principles to allow potential interim access to medicines ahead of NICE’s guidance and are continuing to work with the manufacturer to explore options for interim access to Trodelvy. Following discussion with the manufacturer of Trodelvy, NICE has accelerated its appraisal and now expects to issue guidance in June 2022, with draft guidance expected in spring 2022.